1. Scrip
  2. >>R&D

Sentynl Signs Deal With Fortress’ Cyprium For ‘De-Risked’ Rare Disease Drug

 
• By Alaric DeArment

Deal Snapshot: Sentynl will pay $20m in upfront and regulatory milestone payments through FDA approval, while Cyprium will retain 100% ownership of the priority review voucher.

Handshake of businessmen
Sentynl signed a development and asset purchase agreement for Cyprium's CUTX-101 for Menkes disease, which has approved therapy • Source: Shutterstock

Who: Cyprium Therapeutics (Fortress Biotech)/Sentynl Therapeutics (Zydus Group)

What: On 24 February, Sentynl signed a development and asset purchase agreement for Cyprium’s CUTX-101, a copper histidinate drug for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By Joseph Haas

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 
• By Andrew McConaghie

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger